CORT - Corcept Therapeutics GAAP EPS of $0.14 misses by $0.05 revenue of $105.7M beats by $0.79M

2023-05-03 16:15:53 ET

• Corcept Therapeutics press release ( NASDAQ: CORT ): Q1 GAAP EPS of $0.14 misses by $0.05 .
• Revenue of $105.7M (+12.8% Y/Y) beats by $0.79M .
• Cash and investments of $465.1 million as of March 31, 2023
• Purchase of 6.6 million shares of Corcept common stock for $145.4 million in April 2023

• Cash and investments were $465.1 million at March 31, 2023 compared to $436.6 million at December 31, 2022. In April 2023, Corcept purchased 6.6 million shares of its common stock for $145.4 million

• Raised 2023 revenue guidance to $435 - $455 million, from $430 - $450 million vs $435.70M Consensus

For further details see: